The objective of this proposal is to use redox amplified radionuclide deposition to enable the non-invasive imaging of pancreatic beta-cells in type 1 diabetic patients using positron emission tomography (PET). It is becoming increasingly clear that diabetes is an epidemic and may be one of the 21st century's greatest health concerns. Molecular imaging tools are needed to monitor the progression of disease, the effectiveness of novel therapeutics, and to track the viability of transplanted cells. However, despite this need, the development of a whole-body molecular imaging technique to monitor beta-cells has remained elusive primarily due to inadequate signal-to-background, which prevents the resolution of target rare beta-cells (~1-2% of tissue) against background pancreatic cells. Here we propose an innovative solution, the amplification of PET imaging signals through enzyme catalyzed radionuclide reporter deposition. If successful, this method would represent a fundamentally new approach to signal amplification in radionuclide imaging. Such methods could dramatically increase signal output from beta-cell specific reporters while simultaneously suppressing background. A fundamental analysis of the problem suggests that such novel solutions are a requirement if we hope to detect rare cells using PET imaging. The development of generic methods to amplify PET signals could lead to valuable imaging tools for monitoring beta-cell mass and have an enormous impact on the clinical diagnosis, treatment, and understanding of type 1 diabetes.

Public Health Relevance

This proposal aims to develop greatly improved methods to image small clusters of insulin producing cells. If successful, this would lead to better monitoring of diseased condition so appropriate treatment can be administered, improved understanding of diabetes biology, and tools for tracking the viability of transplanted cells.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
NIH Director’s New Innovator Awards (DP2)
Project #
3DP2DK111801-01S1
Application #
9523535
Study Section
Program Officer
Laughlin, Maren R
Project Start
2016-09-25
Project End
2021-06-30
Budget Start
2016-09-25
Budget End
2021-06-30
Support Year
1
Fiscal Year
2017
Total Cost
Indirect Cost
Name
University of California, San Diego
Department
Chemistry
Type
Schools of Arts and Sciences
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Wu, Haoxing; Devaraj, Neal K (2018) Advances in Tetrazine Bioorthogonal Chemistry Driven by the Synthesis of Novel Tetrazines and Dienophiles. Acc Chem Res 51:1249-1259
Rudd, Andrew K; Devaraj, Neal K (2018) Traceless synthesis of ceramides in living cells reveals saturation-dependent apoptotic effects. Proc Natl Acad Sci U S A 115:7485-7490